Harvard Bioscience, Inc. (Nasdaq: HBIO) and Etisense announced
today that they have entered into an agreement to offer DECRO®,
Etisense’s non-invasive telemetry jacket and associated
physiological monitoring software, to a broad range of pre-clinical
customers in the North American and European markets.
Harvard Bioscience’s Data Sciences International
(DSI) pre-clinical business will serve as the exclusive distributor
of Etisense’s line of DECRO telemetry jackets and software in North
America, the United Kingdom, and Ireland. Etisense will also supply
a dedicated version of its DECRO telemetry jackets to be marketed
by DSI in North America and Europe. These telemetry jackets, which
will expand DSI’s Jacketed External Telemetry (JET™) product line,
will be specially adapted to integrate with DSI’s industry leading
Ponemah™ monitoring and data management software.
DECRO is the first and only of its kind wearable
respiratory, cardiac and physical activity monitoring solution for
small mammalian models, answering unmet scientific and ethical
needs in preclinical research. DECRO provides physiological
endpoints required in safety-pharmacology, pre-IND toxicology
studies of new drug candidates or in pathological research models,
without using invasive or restraining techniques.
This innovative jacket enables low
noise surface electrocardiogram (ECG) and high resolution
Respiratory Inductive Plethysmography (RIP) with sensors integrated
on the jacket and features an inertial motion unit to assess
physical activity while the models move and live freely within
study programs, supporting more true-to-life results.
For DSI’s JET product line, the DECRO jacket
solution will be integrated with DSI’s Ponemah software platform,
the industry’s premier data acquisition and analysis platform,
which supports continuous data acquisition from many subjects and
signal types. The Ponemah platform is designed to meet a broad
range of pre-clinical research needs, including for contract
research organization (CRO) and pharmaceutical customers. The
Ponemah software is available in both good laboratory practice
(GLP) compliant and non-GLP compliant versions.
Jim Green, Harvard Bioscience President and CEO,
said, “Our relationship with Etisense marks another step in
maintaining DSI’s leadership in pre-clinical research and aligns
with Harvard Bioscience’s vision to meet the needs of our larger
industrial customers such as CROs and pharma companies, as well as
leading academic and government labs.”
Serge Savard, Harvard Bioscience Vice President
of Product Management, said, “By integrating Etisense’s jacketed
solution into our DSI portfolio, we further enhance our offering to
toxicology research customers with simplified access to
physiological endpoints. Etisense’s solution brings to customers a
unique offering, either with Etisense’s DECRO as a standalone
solution or integrated with DSI’s Ponemah, opening the
possibilities for combined recordings with behavior studies, by
using our recently announced new behavioral monitoring system.”
“We’re thrilled that this collaboration will
bring non-invasive, small-mammal monitoring to customers across
academic and industrial sectors, expanding our reach beyond Europe
into North American markets.” said Timothé Flenet, PhD, CEO of
Etisense. “And with Harvard Bioscience, there’s no better
scientific, technical, and commercial portfolio to which we can
contribute, to ensure more researchers can generate results with
confidence and serenity.”
Under the new agreement, DSI will serve as the
exclusive distributor of Etisense’s DECRO solution and DSI’s
integrated JET - Ponemah product in the United States, Canada, the
United Kingdom, and Ireland. In the European Union (outside of
Ireland), Etisense will continue commercializing its DECRO product
line, while DSI will commercialize the integrated solution. DECRO
is available immediately and will be transferrable to and
interoperable with DSI’s JET integration once available. The
companies target first deliveries of the JET integration with
Ponemah in the spring of 2024.
For product inquiries or orders:
For US, Canada, UK, and Ireland, please contact
Sales@datasci.com.
For Europe, please contact corinne.simon@etisense.com at
Etisense, or Sales@datasci.com at DSI.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer,
manufacturer and seller of technologies, products and services that
enable fundamental advances in life science applications, including
research, pharmaceutical and therapy discovery, bio-production and
preclinical testing for pharmaceutical and therapy development. Our
customers range from renowned academic institutions and government
laboratories to the world’s leading pharmaceutical, biotechnology
and contract research organizations. With operations in North
America, Europe, and China, we sell through a combination of direct
and distribution channels to customers around the world.
For more information, please visit our website
at https://www.harvardbioscience.com.
About Etisense
Etisense is an innovative biomedical engineering
company based in Lyon, France, specialized in developing
physiological monitoring technologies. The company was created with
the idea that physiological monitoring should be simple and
non-invasive to face the challenges of modern and ethical medical
research. Incorporated in March 2018, as a spin-off of TIMC Lab
(Université Grenoble Alpes, CNRS, Grenoble INP). Etisense’s
expertise ranges from e-textiles to embedded electronics and signal
processing analysis in order to deliver a truly holistic approach
to high performance monitoring.
Etisense’s products are powered by a proprietary
platform for synchronous biosignals acquisition and processing.
This platform is a combination of textile engineering, high
performance sensors and electronics, advanced signal processing
algorithms and modern software experience with full web
technologies.
The company has been supported by funding
from SATT Linksium and Bpifrance throughout its development
phases, by Angels Santé, Hara and a pool of Private Investors for
seed funding roundtable and by EIT-Health and the AURA
region to support commercial development. Etisense is also a
member of the LyonBiopole competitive cluster ecosystem.
For more information visit: www.etisense.com.
Forward-Looking Statements
This document contains forward-looking
statements within the meaning of the federal securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,”
“intend” and similar expressions or statements that do not relate
to historical matters. Forward-looking statements include, but are
not limited to, information concerning expected future financial
and operational performance including revenues, gross margins,
earnings, cash and debt position, growth and the introduction of
new products, and the strength of the Harvard Bioscience, Inc. (the
Company”) market position and business model. Forward-looking
statements are not guarantees of future performance and involve
known and unknown uncertainties, risks, assumptions, and
contingencies, many of which are outside the Company’s control.
Risks and other factors that could cause the Company’s actual
results to differ materially from those described its
forward-looking statements include those described in the “Risk
Factors” section of the Company’s most recently filed Annual Report
on Form 10-K as well as in the Company’s other filings with the
Securities and Exchange Commission. Forward-looking statements are
based on the Company’s expectations and assumptions as of the date
of this document. Except as required by law, the Company assumes no
obligation to update forward-looking statements to reflect any
change in expectations, even as new information becomes
available.
Inquiries:
For HBIO:
CustomersSales@datasci.com
Investors and MediaHarvard Bioscience, Inc.Investor
Relationsinvestors@harvardbioscience.com(508) 893-3120
For Etisense :
Zeyna Ballée+33 6 79 46 94 38zballee@gmail.com
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024